A summary of where things stand. Explains why the govt is reacting in the way it is and why everyone should be so concerned until we know for sure whether this variant is more or less severe...
"Real world data confirm Omicron escape from Pfizer and AstraZeneca vaccines. However, preliminary real world data from the UK’s Health Security Agency suggests that overall vaccine efficacy mirrors antibody responses. The preliminary data contained in its Technical Briefing 31 published on 10 December showed that efficacy of the 2-dose PFE vaccine against the Delta COVID-19 variant fell from c.90% at 2-9 weeks after the second vaccine dose to c. 60% at 6 weeks. The efficacy against the Omicron variant at six weeks was in the mid-30s % range, so almost half as effective as against the Delta variant. The data also show, with caveats, that the efficacy of the AZN vaccine against the Delta variant fell from the high-70s % at 2-9 weeks post the second dose to 40% at six weeks post the second dose. However, the efficacy against the Omicron variant was just above zero at 6 weeks. The caveats on the data with the AZN vaccine are that low numbers of patients overall and a high proportion of elderly patients could have skewed the data, but when vaccine efficacy was starting at a lower level, we believe a greater reduction in efficacy against the Omicron strain makes sense scientifically. Countries that have used the AZN vaccine as the primary vaccine source are arguably more exposed to lower efficacy against Omicron if these data are validated. The Pfizer/BioNTech vaccine as a third dose/booster seems to do its job…for now. On a positive note, real world protection versus Omicron was boosted to 71-76% (source: UKHSA) after the PFE/BNTX vaccine was given as a third/booster dose, whether the PFE/BNTX or AZN vaccine was given as the first two doses. But, these data are limited in sample size. What is clearly not known yet is the duration of protection from the third/booster vaccine dose, given that protection against the Delta variant declined by around 50% from 4 months after the second dose. Scientifically, against a more infectious variant, at best, the same rate of decline in efficacy may be expected, but a more rapid decline would not be a surprise, requiring new Omicron specific vaccines."